Travere Therapeutics Reports Strong Q1 Sales, FDA Full Approval for FILSPARI in FSGS, and Pegtibatinase Study Restart

summarizeSummary

Travere Therapeutics announced strong Q1 financial results, highlighted by significant FILSPARI sales growth and the FDA's full approval of FILSPARI for FSGS, alongside the restart of a key Phase 3 clinical trial.

check_boxKey Events

• Strong Q1 Product Sales Growth

  Net product sales increased by 64% year-over-year to $124.5 million for the three months ended March 31, 2026, primarily driven by an 88% increase in FILSPARI sales to $105.2 million.

• FDA Full Approval for FILSPARI in FSGS

  On April 13, 2026, the FDA granted full (traditional) approval for FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with Focal Segmental Glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only medicine approved for this condition.

• Improved Financial Performance

  The company reported a net loss of $37.1 million for Q1 2026, an improvement from a net loss of $41.2 million in the prior-year period, with operating loss also improving from $(42.7) million to $(36.9) million.

• Pegtibatinase Phase 3 Study Restart

  Enrollment activities for the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (HCU) restarted in the first quarter of 2026, with the first new patient dosed in April 2026, following a voluntary pause to address manufacturing process improvements.

auto_awesomeAnalysis

Travere Therapeutics reported robust first-quarter financial results, with net product sales increasing by 64% year-over-year, primarily driven by an 88% surge in FILSPARI sales. The company also announced a significant regulatory milestone with the FDA granting full approval for FILSPARI in Focal Segmental Glomerulosclerosis (FSGS), establishing it as the first and only approved medicine for this condition. Additionally, the pivotal Phase 3 HARMONY Study for pegtibatinase, a key pipeline candidate, has restarted enrollment following manufacturing process improvements. While the company continues to operate at a net loss and experienced a decrease in its cash and marketable securities, these positive developments in commercial performance and pipeline advancement are critical for its long-term growth and market expansion, especially given the prior 8-K announcing strong Q1 results.